Data Sciences International has appointed Bert Harman to the position of chief executive officer. Harman will be responsible for managing DSI as it enters a phase of growth and increasing market penetration for DSI technologies.
Data Sciences International (DSI) announced the appointment of Bert Harman to the position of chief executive officer. Mr. Harman will be responsible for managing DSI as it enters a phase of significant potential growth and increasing the market penetration for DSI technologies, including the new TruSense® telemetry implants. The first TruSense implant was recently unveiled at the Safety Pharmacology Society conference, held September 19-22, 2011.
Mr. Harman joins DSI from Otto Bock HealthCare, a manufacturer of prosthetic and orthotic devices, where he served as president and CEO from 2000 to 2011. During his tenure at Otto Bock the company realized significant revenue growth. Prior to his position at Otto Bock, Mr. Harman served in a range of positions at 3M Company’s Industrial, International and Health Care Businesses. Harman holds a Bachelor of Science from the University of Baltimore and served in the U.S. Army.
“Bert has a very strong track record of growing businesses out of niche markets and into much broader markets. As such, he was the ideal person to join DSI as CEO at this critical time of expansion for the company,” said Brent Ahrens, general partner at Canaan Partners and the newly appointed chairman of the board for DSI.
“DSI has been the leader in nonclinical physiologic monitoring tools since 1984 and now with the upcoming release of TruSense telemetry implants, we are positioned to expand into new markets, broaden our reach and catapult our growth,” said Mr. Harman. “DSI has a comprehensive portfolio that has served the research community for nearly 30 years. DSI has innovated for the future and I’ll be working to guide the company to achieve its greatest potential.”
Data Sciences International (DSI) offers complete systems for monitoring and collecting data including advanced telemetry implants and receivers along with data acquisition and analysis software. These systems leverage the latest analog or digital technology to turn accurate data into useful information quickly and easily—representing a major advancement in data collection for pharmacological and toxicological studies. Large or small animals can be monitored with minimal stress, 24 hours a day for months at a time. The result is higher-quality data with greater predictive value, allowing accurate and reliable measurement of the true effects of clinical intervention.